192 related articles for article (PubMed ID: 37705995)
1. Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma.
Drumond-Bock AL; Wang L; Wang L; Cybula M; Rostworowska M; Kinter M; Bieniasz M
Genes Cancer; 2023; 14():56-76. PubMed ID: 37705995
[TBL] [Abstract][Full Text] [Related]
2. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Drumond-Bock AL; Bieniasz M
Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
[TBL] [Abstract][Full Text] [Related]
3. CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S; Wilson AJ; Hirst J; Roby KF; Fadare O; Crispens MA; Beeghly-Fadiel A; Khabele D
Gynecol Oncol; 2020 May; 157(2):405-410. PubMed ID: 32044108
[TBL] [Abstract][Full Text] [Related]
4. Amplification of the
Jones DH; Lin DI
Mol Clin Oncol; 2017 Aug; 7(2):301-307. PubMed ID: 28781807
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors.
Gasimli K; Raab M; Mandal R; Krämer A; Peña-Llopis S; Tahmasbi Rad M; Becker S; Strebhardt K; Sanhaji M
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201534
[TBL] [Abstract][Full Text] [Related]
6. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
Rhyasen GW; Yao Y; Zhang J; Dulak A; Castriotta L; Jacques K; Zhao W; Gharahdaghi F; Hattersley MM; Lyne PD; Clark E; Zinda M; Fawell SE; Mills GB; Chen H
PLoS One; 2018; 13(7):e0200826. PubMed ID: 30036377
[TBL] [Abstract][Full Text] [Related]
7. Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival.
Ucar D; Lin DI
Mol Clin Oncol; 2015 Nov; 3(6):1291-1294. PubMed ID: 26807235
[TBL] [Abstract][Full Text] [Related]
8. Expression of DNA Methyltransferase 3B Isoforms Is Associated with DNA Satellite 2 Hypomethylation and Clinical Prognosis in Advanced High-Grade Serous Ovarian Carcinoma.
Del Castillo Falconi VM; Díaz-Chávez J; Torres-Arciga K; Luna-Maldonado F; Gudiño-Gomez AA; Pedroza-Torres A; Castro-Hernández C; Cantú de León D; Herrera LA
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361550
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
Yano M; Miyazawa M; Ogane N; Ogasawara A; Hasegawa K; Narahara H; Yasuda M
Anticancer Res; 2021 Mar; 41(3):1647-1654. PubMed ID: 33788761
[TBL] [Abstract][Full Text] [Related]
10. Conditional Human BRD4 Knock-In Transgenic Mouse Genotyping and Protein Isoform Detection.
Lewis MP; Wu SY; Chiang CM
Bio Protoc; 2022 Apr; 12(7):. PubMed ID: 35530522
[TBL] [Abstract][Full Text] [Related]
11. Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein.
Nunes M; Silva PMA; Coelho R; Pinto C; Resende A; Bousbaa H; Almeida GM; Ricardo S
Front Oncol; 2021; 11():752127. PubMed ID: 34745981
[TBL] [Abstract][Full Text] [Related]
12. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
13. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
Baratta MG; Schinzel AC; Zwang Y; Bandopadhayay P; Bowman-Colin C; Kutt J; Curtis J; Piao H; Wong LC; Kung AL; Beroukhim R; Bradner JE; Drapkin R; Hahn WC; Liu JF; Livingston DM
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):232-7. PubMed ID: 25535366
[TBL] [Abstract][Full Text] [Related]
14. Bromodomain-containing protein 4 silencing by microRNA-765 produces anti-ovarian cancer cell activity.
Ji YJ; Shao Y; Zhang J; Zhang X; Qiang P
Aging (Albany NY); 2021 Mar; 13(6):8214-8227. PubMed ID: 33686960
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
Choi CH; Sung CO; Kim HJ; Lee YY; Song SY; Song T; Kim J; Kim TJ; Lee JW; Bae DS; Kim BG
Hum Pathol; 2013 Jun; 44(6):1017-23. PubMed ID: 23290009
[TBL] [Abstract][Full Text] [Related]
16. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
17. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
[TBL] [Abstract][Full Text] [Related]
18. Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.
Saglam O; Cao B; Wang X; Toruner GA; Conejo-Garcia JR
PLoS One; 2022; 17(2):e0264014. PubMed ID: 35226658
[TBL] [Abstract][Full Text] [Related]
19. Opposing Functions of BRD4 Isoforms in Breast Cancer.
Wu SY; Lee CF; Lai HT; Yu CT; Lee JE; Zuo H; Tsai SY; Tsai MJ; Ge K; Wan Y; Chiang CM
Mol Cell; 2020 Jun; 78(6):1114-1132.e10. PubMed ID: 32446320
[TBL] [Abstract][Full Text] [Related]
20. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
